Takeda Pharmaceutical (NYSE:TAK) Upgraded at Wall Street Zen
by Kim Johansen · The Markets DailyWall Street Zen upgraded shares of Takeda Pharmaceutical (NYSE:TAK – Free Report) from a hold rating to a buy rating in a research report sent to investors on Saturday morning.
A number of other research firms also recently weighed in on TAK. Zacks Research downgraded Takeda Pharmaceutical from a “hold” rating to a “strong sell” rating in a research note on Monday, June 29th. Weiss Ratings cut Takeda Pharmaceutical from a “hold (c)” rating to a “hold (c-)” rating in a research note on Tuesday, June 23rd. Finally, Sanford C. Bernstein upgraded Takeda Pharmaceutical from a “market perform” rating to an “outperform” rating in a report on Wednesday, April 8th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold”.
View Our Latest Stock Analysis on Takeda Pharmaceutical
Takeda Pharmaceutical Trading Down 0.6%
Takeda Pharmaceutical stock opened at $17.05 on Friday. Takeda Pharmaceutical has a 12 month low of $12.99 and a 12 month high of $18.90. The company has a quick ratio of 0.60, a current ratio of 1.09 and a debt-to-equity ratio of 0.59. The stock has a market cap of $54.61 billion, a P/E ratio of 43.71 and a beta of -0.07. The company’s fifty day simple moving average is $16.14 and its 200-day simple moving average is $16.99.
Takeda Pharmaceutical (NYSE:TAK – Get Free Report) last announced its quarterly earnings data on Tuesday, March 31st. The company reported $0.56 earnings per share (EPS) for the quarter. The business had revenue of $6.90 billion during the quarter. Takeda Pharmaceutical had a return on equity of 11.20% and a net margin of 4.31%. As a group, sell-side analysts forecast that Takeda Pharmaceutical will post 1.12 EPS for the current fiscal year.
Institutional Trading of Takeda Pharmaceutical
Several hedge funds have recently added to or reduced their stakes in TAK. Arrowstreet Capital Limited Partnership boosted its holdings in Takeda Pharmaceutical by 100.9% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 5,682,847 shares of the company’s stock valued at $88,596,000 after purchasing an additional 2,854,069 shares during the period. UBS Group AG increased its holdings in shares of Takeda Pharmaceutical by 46.4% during the 3rd quarter. UBS Group AG now owns 5,893,969 shares of the company’s stock worth $86,288,000 after purchasing an additional 1,869,323 shares during the period. Qube Research & Technologies Ltd increased its holdings in shares of Takeda Pharmaceutical by 407.9% during the 3rd quarter. Qube Research & Technologies Ltd now owns 1,775,845 shares of the company’s stock worth $25,998,000 after purchasing an additional 1,426,184 shares during the period. Van ECK Associates Corp raised its position in shares of Takeda Pharmaceutical by 98.4% during the fourth quarter. Van ECK Associates Corp now owns 2,305,397 shares of the company’s stock valued at $35,941,000 after buying an additional 1,143,117 shares during the last quarter. Finally, Voloridge Investment Management LLC raised its position in shares of Takeda Pharmaceutical by 1,070.7% during the fourth quarter. Voloridge Investment Management LLC now owns 962,502 shares of the company’s stock valued at $15,005,000 after buying an additional 880,289 shares during the last quarter. Institutional investors own 9.17% of the company’s stock.
Takeda Pharmaceutical Company Profile
Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.
Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.